Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
June 27th, 2020
Intrinsically disordered domains are important for oncogenic fusion transcription factor function. To therapeutically target these proteins, a more detailed understanding of the regulatory mechanisms employed by these domains is required. Here, we use transcriptomics to map important structural features of the intrinsically disordered EWS domain in Ewing sarcoma.
Overview
This study investigates the role of intrinsically disordered domains in oncogenic fusion transcription factors, focusing on the EWS domain in Ewing sarcoma. By utilizing transcriptomics, the research aims to elucidate the regulatory mechanisms of these disordered regions.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Transcriptional Regulation
Background
- Oncogenic fusion transcription factors often contain intrinsically disordered domains.
- Understanding their regulatory mechanisms is crucial for developing targeted therapies.
- Transcriptomics can reveal structure-function relationships in these proteins.
- Partial function detection is vital for understanding their roles in cancer.
Purpose of Study
- To map structural features of the EWS domain in Ewing sarcoma.
- To improve therapeutic targeting of oncogenic fusion transcription factors.
- To enhance understanding of the regulatory mechanisms of disordered domains.
Methods Used
- RNA sequencing to assess gene regulation by the EWS domain.
- cDNA expression construct transduction in cell cultures.
- Western blot analysis for protein validation.
- DESeq2 for differential expression analysis.
Main Results
- Identification of key structural features of the EWS domain.
- Successful validation of knockdown and expression of constructs.
- Insights into the gene regulatory networks influenced by the EWS domain.
- Establishment of a framework for future studies on disordered domains.
Conclusions
- Intrinsically disordered domains play a significant role in oncogenic transcription factor function.
- Transcriptomics is a powerful tool for uncovering structure-function relationships.
- Findings may inform the development of targeted therapies for fusion-driven cancers.
Frequently Asked Questions
Executive Industry Relevance
Mapping structure-function relationships of disordered oncogenic transcription factors using transcriptomic analysis addresses a critical challenge in target validation for fusion-driven cancers. This approach enables comprehensive functional interrogation of protein domains that lack defined structure, supporting predictive confidence in early discovery and mechanistic de-risking. The method informs portfolio decisions by clarifying which structural features are essential for oncogenic activity and therapeutic targeting.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables systematic interrogation of disordered domain contributions to oncogenic function.
- Supports biological de-risking by linking structural mutations to transcriptional outcomes.
- Facilitates identification of critical target features for therapeutic intervention.
- Improves predictive confidence in target selection for fusion-driven malignancies.
Screening & Assay Development
- Establishes validated cellular systems for downstream transcriptomic and phenotypic screening.
- Delivers quantitative gene expression outputs for robust assay standardization.
- Enables reproducible detection of partial or loss-of-function phenotypes across constructs.
- Supports scalable screening of domain variants for functional impact.
Translational & Preclinical Research
- Aligns transcriptomic signatures with disease-relevant gene networks in Ewing sarcoma.
- Provides continuity from mechanistic discovery to preclinical model validation.
- Enables risk-adjusted advancement of targets with confirmed functional relevance.
- Supports identification of novel gene sets for translational biomarker development.
Pipeline & Workflow Integration
This transcriptomic mapping approach integrates from early discovery through lead identification and preclinical research, supporting iterative hypothesis testing and target prioritization.
- Discovery Biology: Links structural mutations to global gene regulation, clarifying mechanistic drivers of oncogenicity.
- Screening: Provides quantitative, reproducible gene expression profiles for construct comparison.
- Analytics: Enables differential expression, clustering, and principal component analyses to distinguish functional classes.
- Translational Research: Connects in vitro findings to disease-relevant gene sets and phenotypes.
- Enterprise Reuse: Offers a reusable workflow for structure-function mapping of other disordered transcription factors.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Standardizes transcriptomic and phenotypic readouts for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions and capital allocation by clarifying essential target features.
- Portfolio Impact: Enables risk-adjusted prioritization of fusion-driven targets for advancement.
Implementation Considerations
- Requires expertise in transcriptomics, bioinformatics, and functional genomics.
- Demands access to high-throughput sequencing and computational infrastructure.
- Necessitates rigorous cross-batch normalization and quality control for reproducibility.
- Adaptable to other fusion proteins with disordered domains, pending construct availability.
- Dependent on robust phenotypic assays to complement transcriptomic outputs.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:55
In Vitro Construct Panel Setup
2:07
Cell Collection
2:47
Construct Expression Validation and Correlative Phenotypic Assay Setup
3:50
Alignment and Transcript Counting Pipeline
5:32
Differential Expression
7:40
Results: Representative Disordered Oncogenic Transcription Factor Structure-Function Relationship Mapping
9:31
Conclusion
